The combination of Tenofovir 300mg, Emtricitabine 200mg, and Efavirenz 600mg is a fixed-dose antiretroviral therapy used to treat human immunodeficiency virus (HIV) infection. This triple-combination acts by inhibiting HIV replication and increasing CD4+ cell counts, improving immune function. Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI), while emtricitabine and tenofovir are nucleoside reverse transcriptase inhibitors (NRTIs). This medication slows disease progression and reduces the risk of HIV-related complications. It is taken orally once daily, under medical supervision, and is not a cure but helps manage HIV effectively.